Last reviewed · How we verify
MEZLOCILLIN
At a glance
| Generic name | MEZLOCILLIN |
|---|---|
| Drug class | mezlocillin |
| Target | Interleukin-8 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1981 |
Approved indications
- Acute gonococcal cervicitis
- Acute gonococcal endometritis
- Acute gonococcal urethritis
- Aspiration pneumonia
- Bacterial infection due to Klebsiella pneumoniae
- Bacterial infection due to Serratia
- Bacterial septicemia
- Enterobacter Pneumonia
- Genitourinary Tract Infections
- Gonorrhea
- Haemophilus influenzae pneumonia
- Infection of skin AND/OR subcutaneous tissue
- Infectious disease of abdomen
- Pneumonia due to Escherichia coli
- Pneumonia due to Pseudomonas
- Urinary tract infectious disease
Common side effects
Drug interactions
- netilmicin
- tobramycin
Key clinical trials
- Mood and Cognitive Effects of Psilocybin in Healthy Participants (EARLY_PHASE1)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MEZLOCILLIN CI brief — competitive landscape report
- MEZLOCILLIN updates RSS · CI watch RSS